{"protocolSection":{"identificationModule":{"nctId":"NCT03961334","orgStudyIdInfo":{"id":"MOSES"},"organization":{"fullName":"University of Zurich","class":"OTHER"},"briefTitle":"MidregiOnal Proatrial Natriuretic Peptide to Guide SEcondary Stroke Prevention","officialTitle":"MidregiOnal Proatrial Natriuretic Peptide to Guide SEcondary Stroke Prevention: The MOSES-study. An International, Multicentre, Randomised-controlled, Two-arm, Assessor-blinded Trial","acronym":"MOSES"},"statusModule":{"statusVerifiedDate":"2023-08","overallStatus":"RECRUITING","expandedAccessInfo":{"hasExpandedAccess":false},"startDateStruct":{"date":"2019-12-05","type":"ACTUAL"},"primaryCompletionDateStruct":{"date":"2025-01-31","type":"ESTIMATED"},"completionDateStruct":{"date":"2026-01-31","type":"ESTIMATED"},"studyFirstSubmitDate":"2019-05-16","studyFirstSubmitQcDate":"2019-05-21","studyFirstPostDateStruct":{"date":"2019-05-23","type":"ACTUAL"},"lastUpdateSubmitDate":"2023-08-11","lastUpdatePostDateStruct":{"date":"2023-08-16","type":"ACTUAL"}},"sponsorCollaboratorsModule":{"responsibleParty":{"type":"PRINCIPAL_INVESTIGATOR","investigatorFullName":"Mira Katan","investigatorTitle":"Prof. Dr. med.","investigatorAffiliation":"University of Zurich"},"leadSponsor":{"name":"University of Zurich","class":"OTHER"},"collaborators":[{"name":"Swiss National Science Foundation","class":"OTHER"}]},"oversightModule":{"oversightHasDmc":true,"isFdaRegulatedDrug":false,"isFdaRegulatedDevice":false,"isUsExport":false},"descriptionModule":{"briefSummary":"The present trial is addressing the question if a biologically distinct subgroup of ischemic stroke patients without known atrial fibrillation at admission, selected by a cut-off level of MRproANP concentration, which represents a underlying increased risk of cardiac thrombogenicity, benefits from direct oral anticoagulation (DOAC) within 7 days of symptom onset versus standard of care (antiplatelet) as preventive treatment.","detailedDescription":"Three DOACs with marketing authorisation in Switzerland and the EU for the prevention of stroke and systemic embolism in patients with atrial fibrillation can be used. Eligible patients will be randomly assigned to either the standard of care (control) or the experimental (direct start with DOAC) arm with a ratio of 1:1. Each study participant will be observed during a follow up period within one year after index stroke."},"conditionsModule":{"conditions":["Stroke, Ischemic"]},"designModule":{"studyType":"INTERVENTIONAL","phases":["PHASE3"],"designInfo":{"allocation":"RANDOMIZED","interventionModel":"PARALLEL","primaryPurpose":"PREVENTION","maskingInfo":{"masking":"NONE","maskingDescription":"Blinded endpoint assessment by independent CEC"}},"enrollmentInfo":{"count":620,"type":"ESTIMATED"}},"armsInterventionsModule":{"armGroups":[{"label":"DOACs","type":"EXPERIMENTAL","description":"Direct oral anticoagulants","interventionNames":["Drug: Dabigatran","Drug: Apixaban","Drug: Edoxaban"]},{"label":"Antiplatelets","type":"ACTIVE_COMPARATOR","description":"SOC therapy with antiplatelets until study completion or until detection of AF. After detection of AF treatment with DOAC becomes SOC.","interventionNames":["Drug: Aspirin","Drug: Clopidogrel"]}],"interventions":[{"type":"DRUG","name":"Dabigatran","description":"150mg 2x/d","armGroupLabels":["DOACs"],"otherNames":["Pradaxa"]},{"type":"DRUG","name":"Apixaban","description":"5mg 2x/d","armGroupLabels":["DOACs"],"otherNames":["Eliquis"]},{"type":"DRUG","name":"Edoxaban","description":"60mg 1x/d","armGroupLabels":["DOACs"],"otherNames":["Lixiana"]},{"type":"DRUG","name":"Aspirin","description":"100mg 1x/d","armGroupLabels":["Antiplatelets"],"otherNames":["Aspirin cardio"]},{"type":"DRUG","name":"Clopidogrel","description":"75mg 1x/d","armGroupLabels":["Antiplatelets"]}]},"outcomesModule":{"primaryOutcomes":[{"measure":"Recurrent stroke of any type","description":"The primary outcome measure is the time to any recurrent stroke (ischemic, hemorrhagic, unspecified, or fatal stroke)","timeFrame":"within one year after index stroke"}],"secondaryOutcomes":[{"measure":"Composite of major bleeding, recurrent stroke and/or vascular death","description":"Composite of major bleeding, recurrent stroke and/or vascular death (whichever occurs first)","timeFrame":"within one year after index stroke"},{"measure":"Major bleeding, recurrent stroke and/or vascular death as single components","description":"Each single component of the composite in outcome 2 (major bleeding, recurrent stroke and/or vascular death)","timeFrame":"within one year after index stroke"}]},"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Clinical diagnosis of ischemic stroke\n* level ≥200pmol/L within 72 hours from symptom onset\n* Age ≥ 18 years\n* Signed informed consent\n\nExclusion Criteria:\n\n* History of AF, AF on 12-lead ECG on admission or any AF ≥30 seconds during heart-rhythm monitoring prior to randomization\n* Other condition that require anticoagulant therapy (e.g., venous thromboembolism) as per Investigator's judgment including therapeutical dose of low-molecular-weight heparin or heparin\n* Strong likelihood to be treated with prolonged (i.e. more than 30 days) dual antiplatelet therapy during the course of the trial (such as coronary stenting, etc.)\n* Patients undergoing planned procedures where therapy with a DOAC is a contraindication (e.g. surgery)\n* Previous intracranial hemorrhage in the last year\n* Evidence of severe cerebral amyloid angiopathy if MRI scan performed\n* Chronic kidney disease with creatinin clearance \\<30ml/min and or subject who requires haemodialysis or peritoneal dialysis\n* Known bleeding diathesis (e.g. active peptic ulcer disease , platelet count \\< 100'000/mm3 or haemoglobin \\< 9 g/dl or INR ≥ 1.7, documented haemorrhagic tendencies or blood dyscrasias)\n* Active infective endocarditis\n* CT or MRI evidence of cerebral vasculitis\n* Known allergy or intolerance to antiplatelets or DOACs\n* Female who is pregnant or lactating or has a positive pregnancy test at time of admission\n* Current participation in another drug trial","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","stdAges":["ADULT","OLDER_ADULT"]},"contactsLocationsModule":{"centralContacts":[{"name":"Mira Katan, Prof.Dr.med.","role":"CONTACT","phone":"+41 61 328 45 06","email":"mira.katan@usb.ch"}],"overallOfficials":[{"name":"Mira Katan, Prof.Dr.med.","affiliation":"University Hospital, Basel, Switzerland","role":"PRINCIPAL_INVESTIGATOR"}],"locations":[{"facility":"Attikon University Hospital","status":"RECRUITING","city":"Athens","zip":"12462","country":"Greece","contacts":[{"name":"Georgios Tsivgoulis, Prof.Dr.med.","role":"CONTACT","email":"gtsivou@med.uoa.gr"},{"name":"Georgios Tsivgoulis, Prof.Dr.med.","role":"PRINCIPAL_INVESTIGATOR"}],"geoPoint":{"lat":37.97945,"lon":23.71622}},{"facility":"Oslo University Hospital - Ullevål","status":"NOT_YET_RECRUITING","city":"Oslo","zip":"0424","country":"Norway","contacts":[{"name":"Else Charlotte Sandset, Dr. med.","role":"CONTACT","email":"else@sandset.net"},{"name":"Else Charlotte Sandset, Dr. med.","role":"PRINCIPAL_INVESTIGATOR"}],"geoPoint":{"lat":59.91273,"lon":10.74609}},{"facility":"Hospital de la Santa Creu I Sant Pau","status":"RECRUITING","city":"Barcelona","zip":"08041","country":"Spain","contacts":[{"name":"Joan Montaner, MD","role":"CONTACT","email":"jmontaner-ibis@us.es"},{"name":"Joan Montaner, Prof.Dr.med.","role":"PRINCIPAL_INVESTIGATOR"}],"geoPoint":{"lat":41.38879,"lon":2.15899}},{"facility":"Hospital Universitario Virgen Macarena","status":"RECRUITING","city":"Sevilla","zip":"41009","country":"Spain","contacts":[{"name":"Joan Montaner, MD","role":"CONTACT","email":"jmontaner-ibis@us.es"},{"name":"Joan Montaner, Prof.Dr.med.","role":"PRINCIPAL_INVESTIGATOR"}],"geoPoint":{"lat":37.38283,"lon":-5.97317}},{"facility":"Campus Hospital Universitario Virgen del Rocío","status":"RECRUITING","city":"Sevilla","zip":"41013","country":"Spain","contacts":[{"name":"Joan Montaner, MD","role":"CONTACT","email":"jmontaner-ibis@us.es"},{"name":"Joan Montaner, Prof.Dr.med.","role":"PRINCIPAL_INVESTIGATOR"}],"geoPoint":{"lat":37.38283,"lon":-5.97317}},{"facility":"Kantonsspital Aarau, Department of Neurology","status":"RECRUITING","city":"Aarau","state":"Argau","zip":"5001","country":"Switzerland","contacts":[{"name":"Timo Kahles, MD","role":"CONTACT","email":"timo.kahles@ksa.ch"},{"name":"Timo Kahles, Dr. med.","role":"PRINCIPAL_INVESTIGATOR"}],"geoPoint":{"lat":47.39254,"lon":8.04422}},{"facility":"University Hospital of Basel","status":"RECRUITING","city":"Basel","zip":"4031","country":"Switzerland","contacts":[{"name":"Mira Katan, Prof.Dr.med.","role":"CONTACT","email":"Mira.katan@usb.ch"},{"name":"Mira Katan, Prof.Dr.med.","role":"PRINCIPAL_INVESTIGATOR"}],"geoPoint":{"lat":47.55839,"lon":7.57327}},{"facility":"University Hospital of Bern/Inselspital","status":"RECRUITING","city":"Bern","zip":"3010","country":"Switzerland","contacts":[{"name":"David Seiffge, PD Dr. med.","role":"CONTACT","email":"david.seiffge@insel.ch"},{"name":"David Seiffge, PD Dr. med.","role":"PRINCIPAL_INVESTIGATOR"}],"geoPoint":{"lat":46.94809,"lon":7.44744}},{"facility":"Ospedale Regionale di Lugano, Ente Ospedaliero Cantonale","status":"RECRUITING","city":"Lugano","zip":"6900","country":"Switzerland","contacts":[{"name":"Carlo Cereda, MD","role":"CONTACT","email":"carlo.cereda@eoc.ch"},{"name":"Carlo Cereda, PD Dr. med.","role":"PRINCIPAL_INVESTIGATOR"}],"geoPoint":{"lat":46.01008,"lon":8.96004}},{"facility":"Kantonsspital St.Gallen","status":"RECRUITING","city":"St.Gallen","zip":"9007","country":"Switzerland","contacts":[{"name":"Georg Kägi, MD","role":"CONTACT","email":"georg.kaegi@kssg.ch"},{"name":"Georg Kägi, PD Dr. med.","role":"PRINCIPAL_INVESTIGATOR"}],"geoPoint":{"lat":47.42391,"lon":9.37477}},{"facility":"Kantonsspital Winterthur","status":"NOT_YET_RECRUITING","city":"Winterthur","zip":"8401","country":"Switzerland","contacts":[{"name":"Biljana Rodic-Tatic, Dr. med.","role":"CONTACT","email":"biljana.rodic@ksw.ch"},{"name":"Biljana Rodic-Tatic, Dr. med.","role":"PRINCIPAL_INVESTIGATOR"}],"geoPoint":{"lat":47.50564,"lon":8.72413}},{"facility":"University Hospital of Zurich, Department of Neurology","status":"RECRUITING","city":"Zurich","zip":"8091","country":"Switzerland","contacts":[{"name":"Susanne Wegener, Prof.Dr.med.","role":"CONTACT","email":"susanne.wegener@usz.ch"},{"name":"Susanne Wegener, Prof.Dr.med.","role":"PRINCIPAL_INVESTIGATOR"}],"geoPoint":{"lat":47.36667,"lon":8.54999}},{"facility":"Klinik Hirslanden","status":"NOT_YET_RECRUITING","city":"Zürich","zip":"8032","country":"Switzerland","contacts":[{"name":"Nils Peters, Prof.Dr.med.","role":"CONTACT","email":"nils.peters@hirslanden.ch"},{"name":"Nils Peters, Prof.Dr.med.","role":"PRINCIPAL_INVESTIGATOR"}],"geoPoint":{"lat":47.36667,"lon":8.54999}},{"facility":"Queen Elizabeth University Hospital","status":"NOT_YET_RECRUITING","city":"Glasgow","zip":"G51 4TF","country":"United Kingdom","contacts":[{"name":"Jesse Dawson, MD","role":"CONTACT","email":"jesse.dawson@glasgow.ac.uk"},{"name":"Jesse Dawson, Prof.Dr.med.","role":"PRINCIPAL_INVESTIGATOR"}],"geoPoint":{"lat":55.86515,"lon":-4.25763}}]},"ipdSharingStatementModule":{"ipdSharing":"NO"}},"derivedSection":{"miscInfoModule":{"versionHolder":"2024-02-14","removedCountries":["Germany"]},"conditionBrowseModule":{"meshes":[{"id":"D000020521","term":"Stroke"},{"id":"D000083242","term":"Ischemic Stroke"}],"ancestors":[{"id":"D000002561","term":"Cerebrovascular Disorders"},{"id":"D000001927","term":"Brain Diseases"},{"id":"D000002493","term":"Central Nervous System Diseases"},{"id":"D000009422","term":"Nervous System Diseases"},{"id":"D000014652","term":"Vascular Diseases"},{"id":"D000002318","term":"Cardiovascular Diseases"}],"browseLeaves":[{"id":"M21996","name":"Stroke","asFound":"Stroke","relevance":"HIGH"},{"id":"M11997","name":"Neoplasm Metastasis","relevance":"LOW"},{"id":"M10233","name":"Ischemia","relevance":"LOW"},{"id":"M2401","name":"Ischemic Stroke","asFound":"Stroke, Ischemic","relevance":"HIGH"},{"id":"M5500","name":"Cerebrovascular Disorders","relevance":"LOW"},{"id":"M4894","name":"Brain Diseases","relevance":"LOW"},{"id":"M5432","name":"Central Nervous System Diseases","relevance":"LOW"},{"id":"M17090","name":"Vascular Diseases","relevance":"LOW"}],"browseBranches":[{"abbrev":"BC10","name":"Nervous System Diseases"},{"abbrev":"BC14","name":"Heart and Blood Diseases"},{"abbrev":"All","name":"All Conditions"},{"abbrev":"BC04","name":"Neoplasms"},{"abbrev":"BC23","name":"Symptoms and General Pathology"}]},"interventionBrowseModule":{"meshes":[{"id":"D000001241","term":"Aspirin"},{"id":"D000069604","term":"Dabigatran"},{"id":"C000522181","term":"Apixaban"},{"id":"C000552171","term":"Edoxaban"},{"id":"D000077144","term":"Clopidogrel"}],"ancestors":[{"id":"D000000894","term":"Anti-Inflammatory Agents, Non-Steroidal"},{"id":"D000018712","term":"Analgesics, Non-Narcotic"},{"id":"D000000700","term":"Analgesics"},{"id":"D000018689","term":"Sensory System Agents"},{"id":"D000018373","term":"Peripheral Nervous System Agents"},{"id":"D000045505","term":"Physiological Effects of Drugs"},{"id":"D000000893","term":"Anti-Inflammatory Agents"},{"id":"D000018501","term":"Antirheumatic Agents"},{"id":"D000005343","term":"Fibrinolytic Agents"},{"id":"D000050299","term":"Fibrin Modulating Agents"},{"id":"D000045504","term":"Molecular Mechanisms of Pharmacological Action"},{"id":"D000010975","term":"Platelet Aggregation Inhibitors"},{"id":"D000016861","term":"Cyclooxygenase Inhibitors"},{"id":"D000004791","term":"Enzyme Inhibitors"},{"id":"D000058633","term":"Antipyretics"},{"id":"D000058921","term":"Purinergic P2Y Receptor Antagonists"},{"id":"D000058919","term":"Purinergic P2 Receptor Antagonists"},{"id":"D000058914","term":"Purinergic Antagonists"},{"id":"D000058905","term":"Purinergic Agents"},{"id":"D000018377","term":"Neurotransmitter Agents"},{"id":"D000000991","term":"Antithrombins"},{"id":"D000015842","term":"Serine Proteinase Inhibitors"},{"id":"D000011480","term":"Protease Inhibitors"},{"id":"D000000925","term":"Anticoagulants"},{"id":"D000065427","term":"Factor Xa Inhibitors"}],"browseLeaves":[{"id":"M4238","name":"Aspirin","asFound":"Knee","relevance":"HIGH"},{"id":"M288142","name":"Apixaban","asFound":"Extraction","relevance":"HIGH"},{"id":"M1669","name":"Clopidogrel","asFound":"Results","relevance":"HIGH"},{"id":"M3934","name":"Anticoagulants","relevance":"LOW"},{"id":"M260974","name":"Edoxaban","asFound":"Follow-up Study","relevance":"HIGH"},{"id":"M490","name":"Dabigatran","asFound":"4 hours","relevance":"HIGH"},{"id":"M3907","name":"Anti-Inflammatory Agents","relevance":"LOW"},{"id":"M3908","name":"Anti-Inflammatory Agents, Non-Steroidal","relevance":"LOW"},{"id":"M3722","name":"Analgesics","relevance":"LOW"},{"id":"M20476","name":"Analgesics, Non-Narcotic","relevance":"LOW"},{"id":"M20294","name":"Antirheumatic Agents","relevance":"LOW"},{"id":"M8163","name":"Fibrinolytic Agents","relevance":"LOW"},{"id":"M13555","name":"Platelet Aggregation Inhibitors","relevance":"LOW"},{"id":"M18899","name":"Cyclooxygenase Inhibitors","relevance":"LOW"},{"id":"M7641","name":"Enzyme Inhibitors","relevance":"LOW"},{"id":"M28866","name":"Antipyretics","relevance":"LOW"},{"id":"M28984","name":"Purinergic P2Y Receptor Antagonists","relevance":"LOW"},{"id":"M20194","name":"Neurotransmitter Agents","relevance":"LOW"},{"id":"M3997","name":"Antithrombins","relevance":"LOW"},{"id":"M3996","name":"Antithrombin III","relevance":"LOW"},{"id":"M14033","name":"Protease Inhibitors","relevance":"LOW"},{"id":"M18081","name":"Serine Proteinase Inhibitors","relevance":"LOW"},{"id":"M19299","name":"HIV Protease Inhibitors","relevance":"LOW"},{"id":"M30203","name":"Factor Xa Inhibitors","relevance":"LOW"},{"id":"T18","name":"Serine","relevance":"LOW"}],"browseBranches":[{"abbrev":"Antipy","name":"Antipyretics"},{"abbrev":"Infl","name":"Anti-Inflammatory Agents"},{"abbrev":"ARhu","name":"Antirheumatic Agents"},{"abbrev":"FiAg","name":"Fibrinolytic Agents"},{"abbrev":"Analg","name":"Analgesics"},{"abbrev":"PlAggInh","name":"Platelet Aggregation Inhibitors"},{"abbrev":"All","name":"All Drugs and Chemicals"},{"abbrev":"AnCoag","name":"Anticoagulants"},{"abbrev":"Infe","name":"Anti-Infective Agents"},{"abbrev":"AA","name":"Amino Acids"}]}},"hasResults":false}